Clinical Trials Logo

Central Nervous System Neoplasms clinical trials

View clinical trials related to Central Nervous System Neoplasms.

Filter by:

NCT ID: NCT00002875 Completed - Brain Tumors Clinical Trials

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Start date: December 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective when combined with radiation therapy for treating medulloblastoma. PURPOSE: Randomized phase III trial to compare two combination chemotherapy treatments plus radiation therapy in treating children with newly diagnosed medulloblastoma.

NCT ID: NCT00002840 Completed - Clinical trials for Brain and Central Nervous System Tumors

Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma

Start date: August 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, and may be an effective treatment for anaplastic oligodendroglioma. Combining combination chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare radiation therapy with and without combination chemotherapy in patients with resected anaplastic oligodendroglioma.

NCT ID: NCT00002825 Completed - Sarcoma Clinical Trials

Docetaxel in Treating Children With Recurrent Solid Tumors

Start date: January 1997
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of docetaxel in treating children with recurrent solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00002824 Completed - Clinical trials for Brain and Central Nervous System Tumors

Gene Therapy in Treating Patients With Primary Brain Tumors

Start date: February 1996
Phase: Phase 1
Study type: Interventional

RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients with primary brain tumors.

NCT ID: NCT00002814 Completed - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy for Patients With Brain Cancer

Start date: August 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy using paclitaxel and topotecan, plus G-CSF, in treating patients with glioblastoma multiforme or anaplastic astrocytoma that is refractory or recurrent.

NCT ID: NCT00002806 Completed - Clinical trials for Brain and Central Nervous System Tumors

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

Start date: July 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of procarbazine, lomustine, and vincristine followed by radiation therapy in treating adults who have supratentorial glioma.

NCT ID: NCT00002754 Completed - Metastatic Cancer Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

Start date: February 1993
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have primary or metastatic melanoma or brain tumors.

NCT ID: NCT00002753 Completed - Clinical trials for Brain and Central Nervous System Tumors

Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas

Start date: November 1991
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to determine the effectiveness of monoclonal antibody in treating patients with recurrent gliomas.

NCT ID: NCT00002752 Completed - Metastatic Cancer Clinical Trials

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

Start date: February 1993
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have primary or metastatic brain cancer.

NCT ID: NCT00002750 Completed - Lymphoma Clinical Trials

Melphalan in Patients With Neoplastic Meningitis

Start date: December 1992
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of melphalan in patients with persistent or recurrent neoplastic meningitis.